Literature DB >> 9653475

Endoscopically guided frontal sinus beclomethasone instillation for refractory frontal sinus/recess mucosal edema and polyposis.

M J Citardi1, F A Kuhn.   

Abstract

Despite its metabolic complications, systemic corticosteroid therapy remains a mainstay in the treatment of refractory polyposis after endoscopic frontal sinusotomy. Furthermore, topical nasal corticosteroids often fail, presumably due to the relatively small dosage actually absorbed by the polyps. In order to minimize steroid complications while increasing the locally absorbed dose, beclomethasone (approximately 1 cc, 84 mcg/100 microliters) was instilled under endoscopic guidance directly into the frontal sinus in 31 instances in 16 patients with postoperative frontal recess/sinus polyposis and mucosal edema. The frontal recess/sinus polyposis/edema resolved completely in 9 frontal sinuses, improved considerably in 7 frontal sinuses, improved minimally in 5 frontal sinuses, and remained unchanged in 10 frontal sinuses. No complications were noted. AM cortisol levels remained in the normal range. Endoscopically guided frontal sinus beclomethasone instillation should be considered for the treatment of refractory postoperative frontal sinus/recess polyposis/edema. Further basic and clinical research into the pathophysiology of the nasal mucosa is also warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653475     DOI: 10.2500/105065898781390109

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  2 in total

1.  Efficacy and safety of delivery of topical medication on to the frontal sinus at different head positions after frontal sinusotomy.

Authors:  Yu-Xiao Wu; Min Wang; Hui Li; Zhi-Min Xing; Mu-Han Shi; Shi-En Huang; Yan Liu; Cong-Li Geng
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-13       Impact factor: 2.503

Review 2.  The role of endoscopy in the allergist's office.

Authors:  Pete S Batra
Journal:  Curr Allergy Asthma Rep       Date:  2006-05       Impact factor: 4.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.